VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Herpes simplex virus 2 ICP0 mutant vaccine
Vaccine Information
  • Vaccine Name: Herpes simplex virus 2 ICP0 mutant vaccine
  • Target Pathogen: Herpes simplex virus type 1 and 2
  • Target Disease: Herpes
  • Vaccine Ontology ID: VO_0002972
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • ICP0 gene engineering:
    • Type: Gene mutation
    • Description: This ICP0 mutant is from Human herpesvirus type 2 (Halford et al., 2011).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Vaginal immunization
Host Response

Mouse Response

  • Persistence: An ICP0 mutant is attenuated in mice (Halford et al., 2011).
  • Efficacy: An ICP0 mutant induces protection in mice from challenge with wild type HSV-2 (Halford et al., 2011).
  • Host IgG response
    • Description: Immunization with the live-attenuated HSV-2 0ΔNLS virus elicited a significant IgG antibody response directed against HSV-2's entry receptor, gD-2. gD-2 specific IgG antibodies were detected at levels significantly higher than levels detected in naive mice at day 50 after inoculation (Halford et al., 2011).
    • Detailed Gene Information: Click Here.
References
Halford et al., 2011: Halford WP, PĆ¼schel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PloS one. 2011; 6(3); e17748. [PubMed: 21412438].